GLP1R gene variant is associated with glycaemic response to treatment with DPP-4 inhibitors

被引：0
|
作者：
Javorsky, M. [1 ,2 ]
Gotthardova, I. [1 ]
Klimcakova, L. [3 ]
Kvapil, M. [4 ,5 ]
Schroner, Z. [1 ]
Doubravova, P. [4 ]
Zidzik, J. [3 ]
Gal'a, I. [1 ]
Dravecka, I. [6 ]
Tkac, I. [1 ]
机构：
[1] Safarik Univ, Sch Med, Dept Med 4, Kosice, Slovakia
[2] Pasteur Teaching Hosp, Kosice, Slovakia
[3] Safarik Univ, Sch Med, Inst Med Biol & Genet, Kosice, Slovakia
[4] Fac Med 2, Prague, Czech Republic
[5] Fac Hosp Motol, Prague, Czech Republic
[6] Safarik Univ, Sch Med, Dept Med 1, Kosice, Slovakia
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
783
引用
收藏
页码：S373 / S374
页数：2
相关论文
共 50 条
  • [31] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [32] Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
    He, Long
    Li, Jinwei
    Cheng, Xiong
    Luo, Li
    Huang, Yilan
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [33] Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
    Fadini, Gian Paolo
    Avogaro, Angelo
    VASCULAR PHARMACOLOGY, 2011, 55 (1-3) : 10 - 16
  • [34] Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
    Gao, Wenwen
    Liu, Lei
    Huh, Eunna
    Gbahou, Florence
    Cecon, Erika
    Oshima, Masaya
    Houze, Ludivine
    Katsonis, Panagiotis
    Hegron, Alan
    Fan, Zhiran
    Hou, Guofei
    Charpentier, Guillaume
    Boissel, Mathilde
    Derhourhi, Mehdi
    Marre, Michel
    Balkau, Beverley
    Froguel, Philippe
    Scharfmann, Raphael
    Lichtarge, Olivier
    Dam, Julie
    Bonnefond, Amelie
    Liu, Jianfeng
    Jockers, Ralf
    NATURE METABOLISM, 2023, 5 (10) : 1673 - +
  • [35] Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
    Wenwen Gao
    Lei Liu
    Eunna Huh
    Florence Gbahou
    Erika Cecon
    Masaya Oshima
    Ludivine Houzé
    Panagiotis Katsonis
    Alan Hegron
    Zhiran Fan
    Guofei Hou
    Guillaume Charpentier
    Mathilde Boissel
    Mehdi Derhourhi
    Michel Marre
    Beverley Balkau
    Philippe Froguel
    Raphael Scharfmann
    Olivier Lichtarge
    Julie Dam
    Amélie Bonnefond
    Jianfeng Liu
    Ralf Jockers
    Nature Metabolism, 2023, 5 : 1673 - 1684
  • [36] Spontaneous pregnancy under treatment with GLP1R agonist
    Betry, C.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2020, 24 (06): : 212 - 213
  • [37] The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Dara L. Eckerle Mize
    Marzieh Salehi
    Current Diabetes Reports, 2013, 13 : 307 - 318
  • [38] The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Mize, Dara L. Eckerle
    Salehi, Marzieh
    CURRENT DIABETES REPORTS, 2013, 13 (03) : 307 - 318
  • [39] Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
    Aroda, Vanita R.
    Henry, Robert R.
    Han, Jenny
    Huang, Wenying
    DeYoung, Mary Beth
    Darsow, Tamara
    Hoogwerf, Byron J.
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1247 - 1258
  • [40] Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Neumiller, Joshua J.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S16 - S29
12345